Accession Number:

AD1004117

Title:

Could HER2 Heterogeneity Open New Therapeutic Options in Patients with HER2-Primary Breast Cancer

Descriptive Note:

Technical Report,30 Sep 2014,29 Sep 2015

Corporate Author:

Sloan-Kettering Institute for Cancer Research New York United States

Personal Author(s):

Report Date:

2015-10-01

Pagination or Media Count:

9.0

Abstract:

The purpose of this study is to determine if targeted imaging with a HER2 targeting PET tracer can detect HER2-positive metastases in patients with HER2-negative primary breast cancer. An initial nine patients have completed the trial. Five patients demonstrated suspicious foci on 89Zr-trastuzumab PETCT. Two of five patients with suspicious foci had biopsy proven HER2-positive metastases. In this early stage clinical trial, 89Zr-trastuzumab PETCT may detect HER2-positive metastases in patients with HER2-negtive primary breast cancer. This is an initial proof-of-concept that targeted imaging may help identify patients eligible for targeted therapies. The problem of false positive results will need to be addressed.

Subject Categories:

Distribution Statement:

APPROVED FOR PUBLIC RELEASE